February 08, 2024 | 22:42
Increasing footprints in Vietnam in 2023, multinational corporations continue to eye stronger local partnerships to bring more new innovative medicines and vaccines to the local market in 2024 and beyond.
February 01, 2024 | 15:59
Multinational corporations operating in Vietnam are expected to benefit from new legal changes in the months to come, after years of delay.
March 02, 2023 | 10:41
After making gains in 2022, multinational corporations will prioritise strengthening local partnerships to support their ambition of transforming the treatment landscape – but they are also pleading for further legal clarity.
December 07, 2022 | 14:00
More international pharma and medical device businesses are rushing to venture further in Vietnam, anticipating wide growth potential.
December 01, 2022 | 13:00
Multinational corporations in Vietnam are expecting changes in drug rules to make more business and investment progress. Tran Ngoc Anh, representative of the US-ASEAN Business Council, discussed with VIR’s Bich Thuy the current barriers and expectations stemming from legal adjustments.
February 18, 2022 | 14:00
A decade of innovation is in sight for Vietnam’s largest pharmaceutical companies, as long as quick adaption and changes in business strategy are carried out.
August 06, 2021 | 08:00
With risks from interruption of the medical ingredient supply chain and losses in the hospital channel, the Vietnamese pharma industry experienced a topsy-turvy first half of 2021, with potential growth set to focus on mergers and acquisitions.
June 09, 2021 | 20:53
There remains caution over interruption in the ingredient supply chain in Vietnam’s lucrative pharmaceutical industry, but new strategies to intensify growth potential ahead will ensure pharma groups maintain their profitability moving forward.
October 22, 2020 | 09:00
Violations in the pharmaceutical industry are seemingly never-ending, with Young Il Pharm, USV Private, and Armepharco being among recent prominent names. However, future wrongdoings may be better resisted when new stricter rules come into effect next month.
May 19, 2020 | 10:10
The top 10 global pharmaceutical companies are being scrutinised and advised not to prevent or delay a vaccine for COVID-19 from reaching vulnerable people to gain profits, triggering global concerns over their social responsibility.